Targeted Therapeutics for Transthyretin Cardiac Amyloidosis: Proof That Precision Medicine in Heart Failure Is a Possibility?

Sanjiv J. Shah*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations
Original languageEnglish (US)
Pages (from-to)444-447
Number of pages4
JournalCirculation
Volume139
Issue number4
DOIs
StatePublished - Jan 22 2019

Funding

Dr Shah is supported by grants from the National Institutes of Health (R01 HL140731, R01 HL120728, and R01 HL107577) and the American Heart Association (16SFRN28780016 and 15CVGPSD27260148) and by Actelion, Astra-Zeneca, Corvia, and Novartis; and has received consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Cardiora, Eisai, Ionis, Ironwood, Merck, Novartis, Pfizer, Sanofi, and United Therapeutics.

Keywords

  • Editorials
  • amyloidosis
  • heart failure
  • precision medicine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this